MIM
HRMY icon

MetLife Investment Management’s Harmony Biosciences HRMY Stock Holding History

MetLife Investment Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$696K Sell
24,844
-224
-0.9% -$7.34K ﹤0.01% 1593
2025
Q4 		$938K Sell
25,068
-1,290
-5% -$42.4K ﹤0.01% 1469
2025
Q3 		$726K Hold
26,358
– – ﹤0.01% 1629
2025
Q2 		$833K Buy
26,358
+3,579
+16% +$115K ﹤0.01% 1405
2025
Q1 		$756K Sell
22,779
-348
-2% -$12.5K ﹤0.01% 1500
2024
Q4 		$796K Buy
23,127
+5,242
+29% +$180K ﹤0.01% 1537
2024
Q3 		$715K Sell
17,885
-1,397
-7% -$49.1K ﹤0.01% 1584
2024
Q2 		$582K Buy
19,282
+1,735
+10% +$52.2K ﹤0.01% 1642
2024
Q1 		$589K Hold
17,547
– – ﹤0.01% 1585
2023
Q4 		$567K Hold
17,547
– – ﹤0.01% 1612
2023
Q3 		$575K Hold
17,547
– – ﹤0.01% 1546
2023
Q2 		$617K Buy
17,547
+3,275
+23% +$113K ﹤0.01% 1561
2023
Q1 		$466K Hold
14,272
– – ﹤0.01% 1688
2022
Q4 		$786K Hold
14,272
– – 0.01% 1344
2022
Q3 		$632K Hold
14,272
– – 0.01% 1466
2022
Q2 		$696K Buy
14,272
+575
+4% +$25.9K 0.01% 1435
2022
Q1 		$666K Buy
13,697
+4,360
+47% +$178K ﹤0.01% 1599
2021
Q4 		$398K Hold
9,337
– – ﹤0.01% 1630
2021
Q3 		$358K Hold
9,337
– – ﹤0.01% 1721
2021
Q2 		$264K Buy
+9,337
New +$280K ﹤0.01% 1979

Other funds holding HRMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

MetLife Investment Management's HRMY Position: Q1 2026 in Review

MetLife Investment Management reduced its Harmony Biosciences (HRMY) stake by 0.89% in Q1 2026, selling an estimated $7.34K and leaving 24,844 shares worth $696K. The position accounts for ﹤0.01% of the portfolio, ranked #1593.

MetLife Investment Management first reported a position in HRMY in Q2 2021 and has held it in 20 quarters since. The position peaked at $938K in Q4 2025. 309 funds tracked by Wall St. Rank hold HRMY as of Q1 2026.

  • MetLife Investment Management held 24,844 shares of Harmony Biosciences worth $696K as of Q1 2026.
  • MetLife Investment Management sold 224 Harmony Biosciences shares in Q1 2026, an estimated $7.34K.
  • Harmony Biosciences made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #1593 holding.
  • MetLife Investment Management first reported a position in Harmony Biosciences in Q2 2021 and has held it in 20 quarters since.
  • MetLife Investment Management's Harmony Biosciences position peaked at $938K in Q4 2025.
  • 309 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.